Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Open accessThe DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
BACKGROUND: In a phase 1 dose-escalation study, combined inhibition of T-cell checkpoint pathways by nivolumab and ipilimumab was associated with a high rate of objective response, including complete responses, among patients with advanced melanoma. METHODS: In this double-blind study involving 142 patients with metastatic melanoma who had not previously received treatment, we randomly assigned patients in a 2:1 ratio to receive ipilimumab (3 mg per kilogram of body weight) combined with either nivolumab (1 mg per kilogram) or placebo once every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram) or placebo every 2 weeks until the occurrence of disease progression or unacceptable toxic effects. The primary end point was the rate of investigator-assessed, confirmed objective response among patients with BRAF V600 wild-type tumors. RESULTS: Among patients with BRAF wild-type tumors, the rate of confirmed objective response was 61% (44 of 72 patients) in the group that received both ipilimumab and nivolumab (combination group) versus 11% (4 of 37 patients) in the group that received ipilimumab and placebo (ipilimumab-monotherapy group) (P<0.001), with complete responses reported in 16 patients (22%) in the combination group and no patients in the ipilimumab-monotherapy group. The median duration of response was not reached in either group. The median progression-free survival was not reached with the combination therapy and was 4.4 months with ipilimumab monotherapy (hazard ratio associated with combination therapy as compared with ipilimumab monotherapy for disease progression or death, 0.40; 95% confidence interval, 0.23 to 0.68; P<0.001). Similar results for response rate and progression-free survival were observed in 33 patients with BRAF mutation-positive tumors. Drug-related adverse events of grade 3 or 4 were reported in 54% of the patients who received the combination therapy as compared with 24% of the patients who received ipilimumab monotherapy. Select adverse events with potential immunologic causes were consistent with those in a phase 1 study, and most of these events resolved with immune-modulating medication. CONCLUSIONS: The objective-response rate and the progression-free survival among patients with advanced melanoma who had not previously received treatment were significantly greater with nivolumab combined with ipilimumab than with ipilimumab monotherapy. Combination therapy had an acceptable safety profile. (Funded by Bristol-Myers Squibb; ClinicalTrials.gov number, NCT01927419.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence for benefit of nivolumab plus ipilimumab compared to single agent ICI has also been demonstrated in patients with advanced renal cell cancer, microsatellite high/deficient mismatch repair (MSI-hi/dMMR) metastatic colorectal cancer12,14,15, hepatocellular carcinoma16, and non-small cell, EGFR/ALK wild type lung cancer17–19.”
From A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412 (2022) · cites this paper as [14]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 1×
“(% [95% CI])† 44 (61 [49–72]) 4 (11 [3–25]) 12 (52 [31–73]) 1 (10 [0–45])”
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 1×
“Not reported 1 (1) 1 (3) 1 (1) 1 (2) 2 (1)”
Self-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“>ULN 15 (21) 7 (19) 24 (25) 11 (23) 35 (25)”
Self-citationImproved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · cited 3×
“Stable disease 9 (12) 13 (35) 3 (13) 1 (10)”
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“M1b 22 (31) 8 (22) 27 (28) 12 (26) 39 (27)”
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · cited 2×
“Maculopapular rash 15 (16) 3 (3) 8 (17) 0”
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · cited 4×
“Increased lipase 12 (13) 8 (9) 2 (4) 1 (2)”
InfluentialSelf-citationNivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 2×
“Maculopapular rash 15 (16) 3 (3) 8 (17) 0”
Self-citation
Cited by
Items 901–1,000 of 1,008
Ibrahim, T., Mateus, C., Baz, M., & Robert, C. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2219-8 · Cited by 51
Self-citationImmunological Agents Used in Cancer Treatment
Şimşek, M., Tekin, S. B., & Bilici, M. (2019) · Eurasian Journal of Medicine · doi:10.5152/eurasianjmed.2018.18194 · Cited by 54
Miura, J. T., Kroon, H. M., Beasley, G. M., Mullen, D., Farrow, N. E., Mosca, P. J., Lowe, M., Farley, C. R., Kim, Y., Naqvi, S. M. H., et al. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07288-w · Cited by 48
Furuse, M., Kuwabara, H., Ikeda, N., Hattori, Y., Ichikawa, T., Kagawa, N., Kikuta, K., Tamai, S., Nakada, M., Wakabayashi, T., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-06755-y · Cited by 54
Sanchez, V. E., Lynes, J. P., Walbridge, S., Wang, X., Edwards, N. A., Nwankwo, A., Sur, H. P., Dominah, G. A., Obungu, A., Adamstein, N. H., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-67411-w · Cited by 55
Progress in Neoantigen Targeted Cancer Immunotherapies
Han, X.-J., Ma, X.-L., Yang, L., Wei, Y.-Q., Peng, Y., & Wei, X.-W. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00728 · Cited by 47
Strategies in DNA vaccine for melanoma cancer
Rezaei, T., Davoudian, E., Khalili, S., Amini, M. A., Hejazi, M., de la Guárdia, M., & Mokhtarzadeh, A. (2020) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12933 · Cited by 59
Therapeutic Targeting of Checkpoint Receptors within the DNAM1 Axis
Alteber, Z., Kotturi, M. F., Whelan, S., Ganguly, S., Weyl, E., Pardoll, D. M., Hunter, J., & Ophir, E. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1248 · Cited by 52
T cells and monocyte-derived myeloid cells mediate immunotherapy-related hepatitis in a mouse model
Llewellyn, H. P., Arat, S., Gao, J., Wen, J., Xia, S., Kalabat, D., Oziolor, E., Virgen-Slane, R., Affolter, T., & Ji, C. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.06.037 · Cited by 47
Chen, J., Li, S., Yao, Q., Du, N., Fu, X., Lou, Y., Wang, M., Mao, F., Mao, D., Khadaroo, P. A., et al. (2020) · World Journal of Surgical Oncology · doi:10.1186/s12957-020-01933-5 · Cited by 48
Wang, R., Zhuang, J., Zhang, Q., Wu, W., Yu, X., Zhang, H., & Xie, Z. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00689-6 · Cited by 60
Immunotherapy in human colorectal cancer: Challenges and prospective
Sun, X., Suo, J., & Yan, J. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i28.6362 · Cited by 52
Masterful Antibodies: Checkpoint Blockade
Lönberg, N., & Korman, A. J. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0057 · Cited by 52
Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells
Testa, U., Castelli, G., & Pelosi, E. (2017) · Medical Sciences · doi:10.3390/medsci5040028 · Cited by 60
Kottschade, L. A. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0671-4 · Cited by 54
Nivolumab versus ipilimumab in the treatment of advanced melanoma: a critical appraisal
Wan, M. T., & Ming, M. E. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16785 · Cited by 57
Kirchberger, M. C., Moreira, A., Erdmann, M., Schuler, G., & Heinzerling, L. (2018) · Oncotarget · doi:10.18632/oncotarget.25627 · Cited by 49
Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
Tan, I. T., Malinzak, M. D., & Salama, A. K. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0390-2 · Cited by 48
Self-citationBlocking the FSTL1-DIP2A Axis Improves Anti-tumor Immunity
Kudo‐Saito, C., Ishida, A., Shouya, Y., Teramoto, K., Igarashi, T., Kon, R., Saito, K., Awada, C., Ogiwara, Y., & Toyoura, M. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.07.043 · Cited by 48
A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy
Guram, K., Kim, S. S., Wu, V. H., Sanders, P. D., Patel, S. H., Schoenberger, S. P., Cohen, E. E. W., Chen, S., & Sharabi, A. B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00491 · Cited by 62
Addressing the Survivorship Care Needs of Patients Receiving Extended Cancer Treatment
Jacobsen, P. B., Nipp, R. D., & Ganz, P. A. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_175673 · Cited by 50
Abdel-Rahman, O., & Fouad, M. (2016) · Immunotherapy · doi:10.2217/imt-2015-0020 · Cited by 46
Choi, F. D., Kraus, C. N., Elsensohn, A. N., Carley, S. K., Lehmer, L. M., Nguyen, R., Linden, K. G., & Shiu, J. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.05.077 · Cited by 49
Lee, D. Y., Im, E., Yoon, D., Lee, Y., Kim, G., Kim, D., & Kim, S.-H. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.12.001 · Cited by 52
Mechanisms of Immunotherapy Resistance in Cutaneous Melanoma: Recognizing a Shapeshifter
Thornton, J., Chhabra, G., Singh, C. K., Guzmán‐Pérez, G., Shirley, C. A., & Ahmad, N. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.880876 · Cited by 62
Infiltrating plasma cells maintain glioblastoma stem cells through IgG-Tumor binding
Gao, J., Gu, D., Yang, K., Zhang, J., Lin, Q., Yuan, W., Xu, Z., Dixit, D., Gimple, R. C., You, H., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2024.12.006 · Cited by 50
Self-citationUpdates in Therapy for Advanced Melanoma
Singh, B. P., & Salama, A. K. S. (2016) · Cancers · doi:10.3390/cancers8010017 · Cited by 56
Self-citationPham, K., Delitto, D., Knowlton, A. E., Hartlage, E. R., Madhavan, R., Gonzalo, D. H., Thomas, R. M., Behrns, K. E., George, T. J., Hughes, S. J., et al. (2016) · The American Journal of Pathology · doi:10.1016/j.ajpath.2016.02.009 · Cited by 46
Signaling and Immune Regulation in Melanoma Development and Responses to Therapy
Lin, W. M., & Fisher, D. E. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100208 · Cited by 52
Thronicke, A., Steele, M. L., Grah, C., Matthes, B., & Schad, F. (2017) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-017-2045-0 · Cited by 49
Mohamad, O., de Leon, A. D., Schroeder, S. R., Leiker, A. J., Christie, A. L., Zhang-Velten, E. R., Trivedi, L. U., Khan, S. A., Desai, N. B., Laine, A. M., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1440168 · Cited by 46
Treatment‐related toxicities of immune checkpoint inhibitors in advanced cancers: A meta‐analysis
Man, J., Ritchie, G. E., Links, M. J., Lord, S. J., & Lee, C. K. (2018) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12838 · Cited by 49
Leven, C., Padelli, M., Carré, J., Bellissant, É., & Misery, L. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00789-7 · Cited by 53
Immune-Checkpoint Blockade Therapy in Lymphoma
Kuzume, A., Chi, S., Yamauchi, N., & Minami, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155456 · Cited by 49
König, D., & Laubli, H. P. (2020) · Pharmacology · doi:10.1159/000509081 · Cited by 54
Emerging Immunotherapies in the Treatment of Brain Metastases
Nieblas‐Bedolla, E., Nayyar, N., Singh, M., Sullivan, R. J., & Brastianos, P. K. (2020) · The Oncologist · doi:10.1002/onco.13575 · Cited by 52
Dettling, S., Stamova, S., Warta, R., Schnölzer, M., Rapp, C., Rathinasamy, A., Reuß, D., Pocha, K., Roesch, S., Jungk, C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1839 · Cited by 50
Qiu, J., Cheng, Z., Jiang, Z., Gan, L., Zhang, Z., & Xie, Z. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105490 · Cited by 59
“In that analysis, colitis was the most common cause of death arising from an irAE in patients receiving anti-CTLA-4 antibodies (135 of 193 deaths (70%)), and the combination of anti-CTLA-4 and anti-PD-1 antibodies increased the incidence and severity of irAEs [82].”
BackgroundShatila, M., Zhang, H. C., Thomas, A. S., Machado, A. P., Naz, S., Mittal, N., Catinis, C., Varatharajalu, K., Cruz, C. C., Lu, E., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009742 · Cited by 53
Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential
Wurz, G. T., Kao, C.-J., & DeGregorio, M. W. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015615514 · Cited by 53
The Role of Surgery for Melanoma in an Era of Effective Systemic Therapy
Raigani, S., Cohen, S., & Boland, G. M. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0575-8 · Cited by 45
Pulmonary Toxicities from Checkpoint Immunotherapy for Malignancy
Possick, J. D. (2017) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2016.12.012 · Cited by 46
Immune Checkpoint Blockade: The New Frontier in Cancer Treatment
Clarke, J. M., George, D. J., Lisi, S., & Salama, A. K. S. (2018) · Targeted Oncology · doi:10.1007/s11523-017-0549-7 · Cited by 47
Self-citationCurrent status and future perspectives of immunotherapy in bladder cancer treatment
Wu, Z., Liu, J., Dai, R., & Wu, S. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1768-y · Cited by 53
“In UCB, there are several clinical trials for the combination two different ICBs; for instance, a dual therapy obtains a better clinical outcome than those from single agents such as CTLA-4 or PD-L1/ PD1 monotherapy (Postow et al., 2015; Valsecchi, 2015).”
(2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0422-y · Cited by 44
Nivolumab-induced organizing pneumonia in a melanoma patient
Sano, T., Uhara, H., Mikoshiba, Y., Kobayashi, A., Uchiyama, R., Tateishi, K., Yamamoto, H., & Okuyama, R. (2016) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyv199 · Cited by 44
The Promise of Molecularly Targeted and Immunotherapy for Advanced Melanoma
Margolin, K. A. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0421-5 · Cited by 48
Association of the Microbiota and Pancreatic Cancer: Opportunities and Limitations
Chen, Z., Zhang, S., Dong, S., Xu, H., & Zhou, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844401 · Cited by 44
Cheng, L., Chen, L., Shi, Y., Gu, W., Ding, W., Zheng, X. W., Liu, Y., Jiang, J., & Zheng, Z. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01956-6 · Cited by 50
“Furthermore, the ICI combination therapy significantly reduced the risk of disease progression and patient mortality compared with the ipilimumab monotherapy (HR, 0.40) [214].”
ResultInfluentialCombined Immune Therapy for the Treatment of Visceral Leishmaniasis
Faleiro, R. J., Kumar, R., Bunn, P. T., Singh, N., Chauhan, S. B., Sheel, M., Amante, F. H., de, M. M., Edwards, C. L., Ng, S. S., et al. (2016) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0004415 · Cited by 50
Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition
Friedman, C. F., & Postow, M. A. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0509-x · Cited by 46
Self-citationTargeting neoantigens for cancer immunotherapy: Table 1.
Lu, Y., & Robbins, P. F. (2016) · International Immunology · doi:10.1093/intimm/dxw026 · Cited by 49
Abdel-Rahman, O. M. (2016) · Immunotherapy · doi:10.2217/imt-2016-0025 · Cited by 44
Buchbinder, E. I., Gunturi, A., Perritt, J. C., Dutcher, J. P., Aung, S., Kaufman, H. L., Ernstoff, M. S., Miletello, G. P., Curti, B. D., Daniels, G. A., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0155-8 · Cited by 44
Self-citationSpänkuch, I., Gassenmaier, M., Tampouri, I., Noor, S., Forschner, A., Garbe, C., & Amaral, T. M. S. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.018 · Cited by 44
Novel Systemic Therapies for Advanced Gastric Cancer
Kim, H. J., & Oh, S. C. (2018) · Journal of the Korean Gastric Cancer Association · doi:10.5230/jgc.2018.18.e3 · Cited by 46
Anderson, R., & Rapoport, B. L. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00080 · Cited by 47
Patel, R. B., Baniel, C., Sriramaneni, R. N., Bradley, K. A., Markovina, S. T., & Morris, Z. S. (2018) · Brachytherapy · doi:10.1016/j.brachy.2018.07.004 · Cited by 49
The Role of Melanoma Cell-Stroma Interaction in Cell Motility, Invasion, and Metastasis
Ju, R. J., Stehbens, S. J., & Haass, N. K. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00307 · Cited by 48
Programmed Cell Death-1/Ligand-1 PET Imaging
Verhoeff, S. R., van den Heuvel, M. M., van Herpen, C. M. L., Piet, B., Aarntzen, E. H. J. G., & Heskamp, S. (2019) · PET Clinics · doi:10.1016/j.cpet.2019.08.008 · Cited by 45
Immunotherapy for the Treatment of Breast Cancer: Emerging New Data
Mina, L. A., Lim, S., Bahadur, S. W., & Firoz, A. T. (2020) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s184710 · Cited by 66
Basher, F., Dhar, P., Wang, X., Wainwright, D. A., Zhang, B., Sosman, J., Ji, Z., & Wu, J. D. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00896-0 · Cited by 43
Nikolaou, V. A., Apalla, Z., Carrera, C., Fattore, D., Sollena, P., Riganti, J., Segura, S., Freites‐Martínez, A., Lallas, K., Romano, M. C., et al. (2022) · British Journal of Dermatology · doi:10.1111/bjd.21781 · Cited by 44
Could microbial therapy boost cancer immunotherapy?
Snyder, A., Pamer, E. G., & Wolchok, J. D. (2015) · Science · doi:10.1126/science.aad7706 · Cited by 44
Self-citationManagement of Immune Checkpoint Inhibitor–Induced Myocarditis
Thuny, F., Alexandre, J., Salem, J., Mirabel, M., Dolladille, C., Solal, A. C., Cohen, A. A., Éderhy, S., & Cautela, J. (2021) · JACC CardioOncology · doi:10.1016/j.jaccao.2020.12.001 · Cited by 56
“On the one hand, clinical trials have demonstrated that patients with noncardiovascular irAEs may have favorable clinical outcomes even after ICI discontinuation (9).”
BackgroundPD-L1 inhibitors in the pipeline: Promise and progress
Vanella, V., Festino, L., Strudel, M., Simeone, E., Grimaldi, A. M., & Ascierto, P. A. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1365209 · Cited by 44
Tolstrup, L. K., Bastholt, L., Dieperink, K. B., Möller, S., Zwisler, A., & Pappot, H. (2020) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-020-00255-0 · Cited by 44
Novel immune checkpoint targets: A promising therapy for cancer treatments
Patwekar, M., Sehar, N., Patwekar, F., Medikeri, A., Ali, S., Aldossri, R. M., & Rehman, M. U. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111186 · Cited by 46
Li, W., Li, Y., Li, J., Meng, J., Jiang, Z., Chen, Y., Wen, Y., Liu, S., Cheng, X., Mi, S., et al. (2024) · Advanced Science · doi:10.1002/advs.202309770 · Cited by 63
Cancer immunotherapy-induced rheumatic diseases emerge as new clinical entities
Cappelli, L. C., Shah, A. A., & Bingham, C. O. (2016) · RMD Open · doi:10.1136/rmdopen-2016-000321 · Cited by 43
Emerging role of immunotherapy in urothelial carcinoma—Advanced disease
Zibelman, M. R., Ramamurthy, C., & Plimack, E. R. (2016) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2016.10.017 · Cited by 47
BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma
Queirolo, P., & Spagnolo, F. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9660-6 · Cited by 47
Illouz, F., Briet, C., Cloix, L., Corre, Y. L., Baize, N., Urban, T., Martin, L., & Rodien, P. (2017) · Cancer Medicine · doi:10.1002/cam4.1145 · Cited by 45
Overexpression of immunomodulatory mediators in oral precancerous lesions
Gonçalves, A. S., Mosconi, C., Jaeger, F., Wastowski, I. J., de Aguiar, M. C. F., Silva, T. A., Ribeiro‐Rotta, R. F., Costa, N. L., & Batista, A. C. (2017) · Human Immunology · doi:10.1016/j.humimm.2017.09.003 · Cited by 46
Overview of metastatic disease of the central nervous system
Nolan, C. P., & DeAngelis, L. M. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-12-811161-1.00001-3 · Cited by 45
Expert opinion on thyroid complications in immunotherapy
Illouz, F., Drui, D., Caron, P. J., & Cao, C. D. (2018) · Annales d Endocrinologie · doi:10.1016/j.ando.2018.07.007 · Cited by 47
Riefolo, M., Porcellini, E., Dika, E., Broseghini, E., & Ferracin, M. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12412 · Cited by 47
Hepatotoxicity of immune check point inhibitors: Approach and management
Lleò, A., Rimassa, L., & Colombo, M. (2019) · Digestive and Liver Disease · doi:10.1016/j.dld.2019.06.017 · Cited by 44
Wang, R. Y., Gao, C., Raymond, M. B., Dito, G., Kabbabe, D., Shao, X., Hilt, E., Sun, Y. S., Pak, I., Gutierrez, M. E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0526 · Cited by 43
Suzuki, S., Ogawa, T., Sano, R., Takahara, T., Inukai, D., Satou, A., Tsuchida, H., Yoshikawa, K., Ueda, R., & Tsuzuki, T. (2020) · Cancer Science · doi:10.1111/cas.14422 · Cited by 46
Immune Escape Mediated by Exosomal PD‐L1 in Cancer
Lawler, S. E., Nowicki, M. O., Ricklefs, F. L., & Chiocca, E. A. (2020) · Advanced Biosystems · doi:10.1002/adbi.202000017 · Cited by 45
Differential quantities of immune checkpoint-expressing CD8 T cells in soft tissue sarcoma subtypes
Klaver, Y., Rijnders, M., Oostvogels, A. A. M., Wijers, R., Smid, M., Grünhagen, D. J., Verhoef, C. K., Sleijfer, S., Lamers, C., & Debets, R. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000271 · Cited by 47
Yan, Y., Zhang, L., Zuo, Y., Qian, H., & Liu, C. (2020) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-020-00601-6 · Cited by 45
Huang, Q., Zheng, Y., Gao, Z., Yuan, L., Sun, Y., & Chen, H. (2020) · Journal of Cancer · doi:10.7150/jca.49325 · Cited by 48
Shin, Y. E., Kumar, A., & Guo, J. J. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01254-x · Cited by 43
Activity and Safety of First-Line Treatments for Advanced Melanoma: A Network Meta-Analysis
Boutros, A., Tanda, E. T., Croce, E., Catalano, F., Ceppi, M., Bruzzone, M., Cecchi, F., Arecco, L., Fraguglia, M., Pronzato, P., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2023.04.010 · Cited by 52
Lymphoma Immunotherapy: Current Status
Zappasodi, R., de Braud, F., & Nicola, M. D. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00448 · Cited by 50
Update on Mucin-1 immunotherapy in cancer: a clinical perspective
Rivalland, G., Loveland, B. E., & Mitchell, P. L. R. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1088519 · Cited by 44
An increased number of PD-1+ and Tim-3+ CD8+ T cells is involved in immune evasion in gastric cancer
Takano, S., Saito, H., & Ikeguchi, M. (2016) · Surgery Today · doi:10.1007/s00595-016-1305-9 · Cited by 45
Learning from the “tsunami” of immune checkpoint inhibitors in 2015
Kourie, H. R., Awada, G., & Awada, A. H. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.03.017 · Cited by 42
Tan, S., Chen, D., Liu, K., He, M., Song, H., Shi, Y., Liu, J., Zhang, C. W.-H., Qi, J., Yan, J., et al. (2016) · Protein & Cell · doi:10.1007/s13238-016-0337-7 · Cited by 43
Recent Advances in Immunotherapy in Metastatic NSCLC
Bansal, P., Osman, D. I., Gan, G. N., Simon, G. R., & Boumber, Y. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00239 · Cited by 45
Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing
Paluch, B. E., Glenn, S. T., Conroy, J. M., Papanicolau‐Sengos, A., Bshara, W., Omilian, A. R., Brese, E., Nesline, M., Burgher, B., Andreas, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13691 · Cited by 45
Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer
Jenkins, R. W., Thummalapalli, R., Carter, J., Cañadas, I., & Barbie, D. A. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-060116-022926 · Cited by 44
Immune-related adverse events by immune checkpoint inhibitors
Kadono, T. (2017) · Japanese Journal of Clinical Immunology · doi:10.2177/jsci.40.83 · Cited by 47
The new paradigm of systemic therapies for metastatic melanoma
Volpe, V. O., Klufas, D. M., Hegde, U. P., & Grant-Kels, J. M. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.04.1126 · Cited by 45
Chen, B., Li, L., Li, M., & Wang, X. (2020) · Cellular Oncology · doi:10.1007/s13402-020-00534-4 · Cited by 46
“Therefore, to enhance the immunotherapy response in “cold” tumors, combinations of multiple treatment strategies have been investigated, including combinations of different immunotherapies [15] and combinations of immunotherapy and other therapeutic strategies such as chemotherapy, radiotherapy and/or targeted therapi…”
BackgroundRheumatic immune‐related adverse events induced by immune checkpoint inhibitors
Zhong, H., Zhou, J., Xu, D., & Zeng, X. (2020) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13346 · Cited by 43
Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?
Maritaz, C., Broutin, S., Chaput, N., Marabelle, A., & Paci, A. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01182-3 · Cited by 52
“ICI: Immune Checkpoint Inhibitor; CTLA-4: Cytotoxic T lymphocyte antigen-4; PD-1: Programmed cell death protein-1; IgG: Immunoglobulin of isotype G; ORR: Objective response rate; PFS: Progression-free survival; OS: Overall survival; MTD: Maximum tolerated dose; HR: Hazard ratio; ADCC: Antibodydependent cell-mediated c…”
BackgroundInfluentialWhat’s new in melanoma? Combination!
Ascierto, P. A., Marincola, F. M., & Atkins, M. B. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0582-1 · Cited by 47
Metadata
- Authors
- Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., Shaheen, M., Ernstoff, M. S., Minor, D., Salama, A. K., Taylor, M., Ott, P. A., Rollin, L. M., Horak, C., Gagnier, P., Wolchok, J. D., & Hodi, F. S.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Université Paris-Sud (FR)
- Beth Israel Deaconess Medical Center (US)
- From Memorial Sloan Kettering Cancer Center (M.A.P., J.D.W.), Weill Cornell Medical College (M.A.P., J.D.W.), and New York University, Perlmutter Cancer Center (A.C.P.) — all in New York; J. Graham Brown Cancer Center, University of Louisville, Louisville, KY (J.C.); Institute Gustave Roussy, Villejuif (C.R.), Paris-Sud University, Orsay (C.R.), and Institut Universitaire du Cancer, Toulouse (N.M.) — all in France; Huntsman Cancer Institute, Salt Lake City (K.G.); Beth Israel Deaconess Medical Center (D....
- Prisma Health (US)
- Cleveland Clinic (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-05-21
- Volume
- 372
- Issue
- 21
- Pages
- 2006-2017
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5744258
- OpenAlex
- W2128758225
- Cited by
- 2,781
- References
- 28
- Citations by year
- 2026: 53 · 2025: 91 · 2024: 131 · 2023: 175 · 2022: 174 · 2021: 206 · 2020: 261 · 2019: 277 · 2018: 372 · 2017: 449 · 2016: 402 · 2015: 183
- FWCI
- 204.70
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- nivolumab, ipilimumab, metastatic melanoma, combination immunotherapy, immune checkpoint inhibitors, PD-1 inhibitors, CTLA-4 inhibitors, objective response rate, progression-free survival, BRAF V600 mutation, immune-related adverse events, first-line therapy, dose escalation, complete response, duration of response
- MeSH terms
- Ipilimumab, Nivolumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Double-Blind Method, Female, Humans, Male, Melanoma, Middle Aged, Disease-Free Survival, Tumor Burden, Proto-Oncogene Proteins B-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.